Tyumen, Tyumen, Russian Federation
Tyumen, Tyumen, Russian Federation
employee
Tyumen, Tyumen, Russian Federation
UDC 616.31
Background data. A clinical case of mucormycosis of the cranio-maxillofacial region, which occurred as a complication after a new coronavirus infection (COVID-19), against the background of diabetes mellitus and therapy of the underlying disease with glucocorticosteroids (GCS). Subject. COVID-19 is a possible cause of the development of potentially dangerous complications, a special place among which is occupied by mycotic complications, and in particular, mucormycosis of the cranio-maxillofacial region. In the vast majority of cases, this complication was found in patients who underwent COVID-19, were on GCS therapy and had a history of type 2 diabetes mellitus. Objective. To study and describe a case of mucormycosis of the cranio-maxillofacial region, which occurred as a complication after COVID-19 on the background of GCS treatment. Materials and methods. We analyzed the medical records of a patient with mucormycosis of the cranio-maxillofacial region, which occurred as a complication after COVID-19, on the background of hormonal therapy and the presence of diabetes mellitus in the anamnesis. Results. A patient with mucormycosis of the right and left upper jaw, sinuses, zygomatic bone and arch on the left side, developed against the background of COVID-19, was urgently hospitalised in the department of maxillofacial and plastic surgery of the Regional Clinical Hospital No.2 in Tyumen. During his stay in hospital, he received surgical, antimicrobial and intensive medical care. After treatment he was discharged with residual neurological consequences and defects of the middle facial zone structures. Conclusions. 1. The cause of mucormycosis of cranio-maxillofacial region is the decrease of organism resistance against the background of COVID-19 and GCS therapy. 2. Changes of vascular wall characteristic for patients with diabetes mellitus and arterial hypertension also create conditions for lightning angioinvasive spread of mucormycosis.
cranio-maxillofacial mucormycosis, COVID-19, diabetes mellitus, angioinvasion, clinical case
1. Elizbaryan I.S., Lazareva L.A., Semenov F.V., Chuprinenko L.M., Vartanyan S.A., Bayduev C.Z. i dr. Mukormikoz rinoorbital'noy lokalizacii u pacientov s postkovidnym sindromom. Kliniko-morfologicheskie osobennosti. Rossiyskaya rinologiya. 2023;31(1):66‑75. [Elizbaryan I.S., Lazareva L.A., Semenov F.V., Chuprinenko L.M., Vartanyan S.A., Baiduev Ts.Z. et al. Rhinoorbital mucormycosis in patients with the post-COVID syndrome. Clinical and morphological features. Russian Rhinology. 2023;31(1):66‑75. (In Russ.)]. https://doi.org/10.17116/rosrino20233101166
2. Petrikkos G., Skiada A., Drogari-Apiranthitou M. Epidemiology of mucormycosis in Europe. Clinical microbiology and infection. 2014;20(Suppl 6):67-73. https://doi.org/10.1111/1469-0691.12563
3. Klimko N.N., Hostelidi S.N., Shadrivova O.V., Bogomolova T.S., Avdeenko Yu.L., Volkova A.G. i dr. Invazivnyy mukormikoz u onkogematologicheskih bol'nyh (rezul'taty prospektivnogo issledovaniya). Onkogematologiya. 2017;12(2):14-22. [Klimko N.N., Khostelidi S.N., Shadrivova O.V., Bogomolova T.S., Avdeenko Y.L., Volkova A.G. et al. Mucormycosis in oncohematology patients (results of the prospective study). Oncohematology. 2017;12(2):14-22. (In Russ.)]. https://doi.org/10.17650/1818-8346-2017-12-2-14-22
4. Hoenigl M., Seidel D., Carvalho A., Rudramurthy S.M., Arastehfar A., Gangneux J.P. et al. The emergence of COVID-19 associated mucormycosis: Analysis of cases from 18 countries. The Lancet. Microbe. 2022;3(7):e543-e552. https://doi.org/10.1016/S2666-5247(21)00237-8
5. Rocha I.C.N., Hasan M.M., Goyal S., Patel T., Jain S., Ghosh A. et al. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India. Tropical medicine & international health. 2021;26(9):1016-1018. https://doi.org/10.1111/tmi.13641
6. Rudramurthy S.M., Hoenigl M., Meis J.F., Cornely O.A., Muthu V., Gangneux J.P. et al. ECMM/ ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64(9):1028-1037. https://doi.org/10.1111/myc.13335
7. Koehler P., Cornely O.A., Bottiger B.W., Dusse F., Eichenauer D.A., Fuchs F. et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528-534. https://doi.org/10.1111/myc.13096
8. Hostelidi S.N., Zaycev V.A., Vartanyan S.A., Nikitin N.A., Evtuh G.N., Gilyalov M.N. i dr. Mukormikoz u bol'nyh COVID-19 v Rossii: rezul'taty prospektivnogo mnogocentrovogo issledovaniya. Zhurnal infektologii. 2022;14(2):116-127. [Khostelidi S.N., Zaitsev V.A., Vartanyan S.A., Nikitin N.A., Evtukh G.N., Gilalov M.N. et al. Mucormycosis in patients with COVID-19 in Russia: the results of a prospective multi-center study. Journal Infectology. 2022;14(2):116-127. (In Russ.)]. https://doi.org/10.22625/2072-6732-2022-14-2-116-127
9. Jeong W., Keighley C., Wolfe R., Lee W.L., Slavin M.A., Kong D.C.M. et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clinical Microbiology and Infection. 2019;25(1):26-34. https://doi.org/10.1016/j.cmi.2018.07.011.
10. Zurl C., Hoenigl M., Schulz E., Hatzl S., Gorkiewicz G., Krause R. et al. Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological MalignancyJournal of fungi (Basel). 2021;7(2):88. https://doi.org/10.3390/jof7020088
11. Salmanton-García J., Sprute R., Stemler J., Bartoletti M., Dupont D., Valerio M. et al. FungiScope European Confederation of Medical Mycology/The International Society for Human and Animal Mycology Working Group. COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. Emerging infectious diseases. 2021;27(4):1077-1086. https://doi.org/10.3201/eid2704.204895
